Molecure

Molecure is a clinical stage biopharmaceutical company that uses its world leading medicinal chemistry capabilities to discover and develop first in class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases. Molecure has generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally. Molecures lead drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of fibrotic and inflammatory diseases, including interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis (IPF). The phase I study was completed in...

Small molecule drug discovery,immuno-oncology,medicinal chemistry,pharmaceuticals,,inflammatory diseases,fibrotic diseases,chitinase,arginase,and respiratory diseases,cancer,immunotherapy,small molecule immunomodulators

Molecure operates in the Biotechnology research industry.

Molecure's revenue is 11m - 100m

Molecure has 51 - 200 employees.